The Indian Clinical Trial Industry, considered as the booming sector and perceived as a potentially upcoming segment, is undergoing turmoil today with a decline of 9.60 per cent in revenues, with further decline because of delay/decreased clinical trial approvals.
Rajashree Devarakonda
2013- Pharma Bio World
Download the full publication now
Fill in the form to download the content
publication by
Rajashree Devarakonda, MBBS, M.Sc., CCRP, RAC(US/EU), EGMP
Chief Scientific Officer
As Chief Scientific Officer (CSO) and a member of the Executive and Operations Committees, Raj is responsible for directing, leading,…
View profile
all our resources 
